The transducer and the receptor subtype are both bound, and both are more specific than their counterparts in the histamine modules, because the ontology happens to cover this receptor better. GO:0004941 beta2-adrenergic receptor activity names the subtype, where h1_receptor_antagonism and h2_receptor_antagonism both had to sit on GO:0004969 histamine receptor activity because GO has no subtype-specific histamine receptor terms. GO:0071880 is adrenergic-specific, where the H2 module could only use the generic GO:0007189. The difference is ontology coverage, not a claim that this receptor is better understood. Desensitisation is a mechanism node here, not a knowledge gap, because the cited review states the mechanism: phosphorylation by beta-ARK and uncoupling from Gs after beta-arrestin binding. In h2_receptor_antagonism the comparable tolerance is a KNOWLEDGE_GAP, because its source says the mechanism remains unclear; and in this module the variability in who benefits from a long-acting agonist is also a gap, because the cited review says genotypic and phenotypic explanations have not been demonstrated. The three differ according to what their sources state, not according to any judgement about the drug classes. The monotherapy claim is scoped carefully. PMID:21659855 (2011) states that long-acting agonists are not recommended as monotherapy, and PMID:26949137 (2016) is the large trial showing that the fixed-dose combination with an inhaled corticosteroid carries no significantly higher risk of serious asthma-related events than the corticosteroid alone. No source cited here covers the subsequent regulatory history, so the module asserts the trial result and the recommendation and says nothing about boxed warnings. Conformers include airway-disease entries and a toxicological one (Formaldehyde_Poisoning), so the module is not tied to asthma. The current conformer list is read from the entries themselves (`just list-modules`, `just check-conformance-content`), not from this paragraph. Sulfur_Mustard_Poisoning is not a conformer: its salmeterol is bound at CHEBI:9011, but that treatment's own target_mechanisms record an anti-inflammatory rather than a bronchodilator use, so routing it here would assert the wrong action.
Why do some patients, including steroid-naive patients, not obtain the benefit most asthmatic patients get from adding a long-acting beta2 agonist?
KNOWLEDGE GAP
beta2_agonist_response_variability
Attached to:
Receptor Desensitisation and Downregulation on Continued Agonist Exposure
The cited review reports that a small proportion of patients may not benefit from a long-acting agonist and states outright that studies have not clearly demonstrated genotypic or phenotypic differences explaining the variability in response. It is a genuine biological unknown rather than an uncurated fact: the measurements exist, the variability is agreed, and no explanation has been established. It matters to this module because the same review's recommendation that the class not be used as monotherapy rests partly on that unexplained variability, and because the receptor polymorphisms the other cited review describes are the obvious candidate explanation and have not settled it. The Arg16Gly variant is recorded on the desensitisation node as a property of the receptor; what is not asserted anywhere is that it accounts for who responds.
Proposed experiments:
Genotype-stratified prospective cohort of long-acting agonist response
Beta2 Adrenergic Receptor Agonist Occupancy
trigger
A beta2 agonist binds and activates the beta2 adrenergic receptor on airway smooth muscle. The receptor is widely distributed in the respiratory tract and particularly in that muscle, which is what makes an inhaled agonist a targeted bronchodilator rather than a systemic one. The agonists are not a uniform group: the cited review distinguishes those that activate the receptor directly from those taken up into a membrane depot and those binding a receptor-specific auxiliary site, and those differences set the onset and duration that separate short- from long-acting use.
Used by disorders
Asthma
as Beta2 Agonist Occupancy of Airway Smooth Muscle Receptors
Downstream
-
Gs-Coupled Adenylate Cyclase Activation and cAMP Generation
-
Receptor Desensitisation and Downregulation on Continued Agonist Exposure
Show evidence (2 references)
"beta2-receptors being widely distributed in the respiratory tract, particularly in airway smooth muscle"
Places the receptor this node binds in the tissue the module is scoped to, which is why an inhaled agonist acts where it does.
"beta2-Agonists have been characterized as those that directly activate the receptor (albuterol), those that are taken up into a membrane depot (formoterol), and those that interact with a receptor-specific auxiliary binding site (salmeterol)."
Records that occupancy is achieved by three different routes across the class, which is the basis of the short- and long-acting treatments below rather than a difference in the receptor.
Gs-Coupled Adenylate Cyclase Activation and cAMP Generation
effector
Signalling from the occupied receptor runs through a trimeric Gs protein coupled to adenylate cyclase, raising cAMP. The step is bound rather than inferred because the cited review states it. The same review notes cAMP-independent routes, through membrane maxi-K+ channels and through Gi to the MAP kinase system, which this module does not assert: they are named in the source without being tied to the relaxation this chain describes.
Downstream
-
Airway Smooth Muscle Relaxation
Show evidence (1 reference)
"Intracellular signaling following beta2-adrenoceptor activation is largely affected through a trimeric Gs protein coupled to adenylate cyclase."
The transducer this node binds, stated by the source rather than inferred. Note the source's own hedge, "largely", which is why the alternative routes it names are left unasserted.
Airway Smooth Muscle Relaxation
central effector
cAMP relaxes airway smooth muscle by phosphorylating muscle regulatory proteins and lowering cytosolic calcium. This is the module's key conformance target: it is the step that every airway use of a beta2 agonist passes through, and the point at which this module's chain diverges from the receptor's other tissue-specific effects.
Downstream
-
Bronchodilation and Relief of Airflow Obstruction
Show evidence (1 reference)
"Cyclic AMP (cAMP) induces airway relaxation through phosphorylation of muscle regulatory proteins and attenuation of cellular Ca2+ concentrations."
States both the effector and the two mechanisms behind it, which is why this node is DIRECT where an inferred relaxation step would not be.
Bronchodilation and Relief of Airflow Obstruction
consequence
Relaxed airway smooth muscle widens the airway, which relieves airflow obstruction and the symptoms that follow from it. Added to an inhaled corticosteroid, a long-acting agonist also lowers the rate of severe exacerbations, which is a different and longer-run benefit from the immediate bronchodilation and is measured in the trial cited here.
Show evidence (2 references)
"These differences in mechanism of action are reflected in the kinetics of airway smooth muscle relaxation and bronchodilation in patients with asthma."
Ties the relaxation above to bronchodilation in patients. INDIRECT because the sentence is about how the agents differ in kinetics, and the bronchodilation is the shared outcome it assumes rather than reports.
"The risk of a severe asthma exacerbation was 21% lower in the fluticasone-salmeterol group than in the fluticasone-only group"
The exacerbation benefit of adding a long-acting agonist to an inhaled corticosteroid, measured in an 11,679-patient randomised trial.
Receptor Desensitisation and Downregulation on Continued Agonist Exposure
adverse effect
Continued agonist exposure desensitises the receptor. The mechanism is stated rather than unknown: phosphorylation by beta-adrenoceptor kinase uncouples the receptor from Gs after beta-arrestin binds, with internalisation, recycling and downregulation of receptor gene expression behind the longer-run loss. The extent differs by cell and tissue type, which is the source's own explanation for why clinical tolerance to chronic therapy varies. The Gly16 receptor variant downregulates more and is associated with worse asthma, which is recorded here as a property of the receptor rather than as a separate node.
Show evidence (2 references)
"beta-Adrenoceptor desensitization associated with beta2-agonist activation is a consequence of phosphorylation by beta-ARK and uncoupling of the receptor from Gs following beta-arrestin binding"
The stated mechanism for this node. Worth contrasting with h2_receptor_antagonism, where tolerance is a knowledge gap because its source says the mechanism is unclear; here the source supplies it.
"The Gly 16 receptor downregulates to a greater extent and is associated with increased airway hyperreactivity, nocturnal symptoms, and more severe asthma."
A receptor variant that modifies the degree of downregulation this node describes, and the one polymorphism the source ties to a clinical picture.
Serious Asthma Event Risk Governing Use Without an Inhaled Corticosteroid
adverse effect
The safety question that shapes how this class is given. Earlier trials raised a potential risk of serious asthma-related events with long-acting agonists, and the cited review records that they are therefore not recommended as monotherapy or without optimising the inhaled corticosteroid dose. A later 11,679-patient randomised trial found no significantly higher risk of serious asthma-related events for the fixed-dose combination with an inhaled corticosteroid than for the corticosteroid alone. The node is scoped to that pair of claims: it says what the trial measured and what the recommendation is, and nothing about the regulatory history, which no source cited here covers. The node has no upstream edge, and that is the claim: the sources report a risk *associated with* the class, and the one trial here that tested the combination found no significant excess, so nothing cited establishes that receptor occupancy causes these events. An edge from occupancy would assert a mechanism the evidence does not supply -- the same decision taken for the anticholinergic node in h1_receptor_antagonism.
Show evidence (3 references)
"In two large clinical trials, investigators found a potential risk of serious asthma-related events associated with LABAs."
The signal that motivated the trial, quoted from its background section. Graded HUMAN_CLINICAL because the evidence it describes is human trial data, with quote_role BACKGROUND because this paper is reporting earlier trials rather than its own result.
"long-acting β2-agonists are not recommended for use as monotherapy or without optimization of inhaled corticosteroid dose"
The recommendation that follows, in the review's own words. This is why the long-acting treatment below is the corticosteroid-combination one rather than a monotherapy.
"Patients who received salmeterol in a fixed-dose combination with fluticasone did not have a significantly higher risk of serious asthma-related events than did those who received fluticasone alone."
The trial's own finding on the combination, which is the claim this node makes about current use. It bears on the combination and not on monotherapy, which the trial did not test.
Short-Acting Beta2 Agonist Therapy
Platform:
Small molecule
Inhaled albuterol, given for immediate relief of airflow obstruction. Its place in the class is set by how it reaches the receptor: the cited review groups it with the agents that activate the receptor directly, which is the basis of its rapid onset and short duration.
Evidence: 1
Long-Acting Beta2 Agonist Therapy Combined With an Inhaled Corticosteroid
Platform:
Small molecule
Salmeterol or formoterol together with an inhaled corticosteroid, for maintenance rather than rescue. The corticosteroid is part of the treatment and not a separate consideration: the cited review records that long-acting agonists are not recommended as monotherapy, and the trial cited measured the fixed-dose combination rather than the agonist alone. Kept separate from the short-acting treatment because the clinical decision, the evidence base and the required co-therapy all differ.
Evidence: 2